{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T20:18:20Z","timestamp":1787948300318,"version":"build-2784847793"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s13555-025-01337-x","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T08:55:13Z","timestamp":1738918513000},"page":"453-462","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Deucravacitinib: Adverse Events of Interest Across Phase\u00a03 Plaque Psoriasis Trials"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6514-4353","authenticated-orcid":false,"given":"Joseph F.","family":"Merola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3000-2165","authenticated-orcid":false,"given":"Laura K.","family":"Ferris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2906-3867","authenticated-orcid":false,"given":"Jeffrey M.","family":"Sobell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7789-6915","authenticated-orcid":false,"given":"Howard","family":"Sofen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Osborne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Vaile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Ming","family":"Jou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Daamen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Scotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Scharnitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"issue":"502","key":"1337_CR1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw1736","volume":"11","author":"JR Burke","year":"2019","unstructured":"Burke JR, Cheng L, Gillooly KM, et al. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain. Sci Transl Med. 2019;11(502):eaaw1736.","journal-title":"Sci Transl Med"},{"key":"1337_CR2","unstructured":"Sotyktu [package insert]. Princeton, NJ, USA: Bristol Myers Squibb, 2022."},{"key":"1337_CR3","unstructured":"Sotyktu [European summary of product characteristics]. Dublin, Ireland: Bristol Myers Squibb EEIG, 2023."},{"key":"1337_CR4","unstructured":"Sotyktu [package insert]. Tokyo, Japan: Bristol Myers Squibb K.K., 2022."},{"key":"1337_CR5","unstructured":"Sotyktu [product monograph]. Montreal, QC, Canada: Bristol Myers Squibb Canada Co., 2022."},{"key":"1337_CR6","unstructured":"Sotyktu [product information]. Mulgrave, VIC, Australia: Bristol Myers Squibb Australia Pty. Ltd., 2022."},{"issue":"20","key":"1337_CR7","doi-asserted-by":"publisher","first-page":"8973","DOI":"10.1021\/acs.jmedchem.9b00444","volume":"62","author":"ST Wrobleski","year":"2019","unstructured":"Wrobleski ST, Moslin R, Lin S, et al. Highly selective inhibition of tyrosine kinase\u00a02 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165. J Med Chem. 2019;62(20):8973\u201395.","journal-title":"J Med Chem"},{"key":"1337_CR8","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.4688","author":"AW Armstrong","year":"2024","unstructured":"Armstrong AW, Lebwohl M, Warren RB, et al. Safety and efficacy of deucravacitinib in moderate to severe plaque psoriasis for up to 3\u00a0years: a nonrandomized open-label extension of phase\u00a03 clinical trials. JAMA Dermatol. 2024. https:\/\/doi.org\/10.1001\/jamadermatol.2024.4688.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1337_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","volume":"88","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase\u00a03 POETYK PSO-1 trial. J Am Acad Dermatol. 2023;88(1):29\u201339.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1337_CR10","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","volume":"88","author":"B Strober","year":"2023","unstructured":"Strober B, Tha\u00e7i D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, program for evaluation of TYK2 inhibitor psoriasis second phase\u00a03 trial. J Am Acad Dermatol. 2023;88(1):40\u201351.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1337_CR11","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1093\/bjd\/ljae014","volume":"190","author":"M Lebwohl","year":"2024","unstructured":"Lebwohl M, Warren RB, Sofen H, et al. Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase\u00a03 POETYK trials. Br J Dermatol. 2024;190(5):668\u201379.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1337_CR12","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/bjd.12214","volume":"168","author":"KA Papp","year":"2013","unstructured":"Papp KA, Griffiths CE, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5\u00a0years of follow-up. Br J Dermatol. 2013;168(4):844\u201354.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1337_CR13","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.jaad.2021.11.004","volume":"86","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Tsai TF, Langley RG, et al. Consistent safety profile with up to 5\u00a0years of continuous treatment with guselkumab: pooled analyses from the phase\u00a03 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis. J Am Acad Dermatol. 2022;86(4):827\u201334.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1337_CR14","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/bjd.20818","volume":"186","author":"KB Gordon","year":"2022","unstructured":"Gordon KB, Lebwohl M, Papp KA, et al. Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2022;186(3):466\u201375.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1337_CR15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13075-019-1882-2","volume":"21","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Mease PJ, McInnes IB, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019;21(1):111.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"1337_CR16","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.jid.2017.10.005","volume":"138","author":"ZZN Yiu","year":"2018","unstructured":"Yiu ZZN, Smith CH, Ashcroft DM, et al. Risk of serious infection in patients with psoriasis receiving biologic therapies: a prospective cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2018;138(3):534\u201341.","journal-title":"J Invest Dermatol"},{"issue":"9","key":"1337_CR17","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamadermatol.2015.0718","volume":"151","author":"RE Kalb","year":"2015","unstructured":"Kalb RE, Fiorentino DF, Lebwohl MG, et al. Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JAMA Dermatol. 2015;151(9):961\u20139.","journal-title":"JAMA Dermatol"},{"issue":"10","key":"1337_CR18","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00403-015-1593-8","volume":"307","author":"K Reich","year":"2015","unstructured":"Reich K, Mrowietz U, Radtke MA, et al. Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest. Arch Dermatol Res. 2015;307(10):875\u201383.","journal-title":"Arch Dermatol Res"},{"issue":"2","key":"1337_CR19","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1136\/annrheumdis-2019-216102","volume":"79","author":"X Li","year":"2020","unstructured":"Li X, Andersen KM, Chang HY, Curtis JR, Alexander GC. Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis. Ann Rheum Dis. 2020;79(2):285\u201391.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1337_CR20","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1001\/jamadermatol.2019.1121","volume":"155","author":"ED Dommasch","year":"2019","unstructured":"Dommasch ED, Kim SC, Lee MP, Gagne JJ. Risk of serious infection in patients receiving systemic medications for the treatment of psoriasis. JAMA Dermatol. 2019;155(10):1142\u201352.","journal-title":"JAMA Dermatol"},{"issue":"23","key":"1337_CR21","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19. N Engl J Med. 2021;384(23):2187\u2013201.","journal-title":"N Engl J Med"},{"key":"1337_CR22","unstructured":"COVID-19 Weekly Epidemiological Update Edition 96. World Health Organization, 2022. https:\/\/www.who.int\/publications\/m\/item\/weekly-epidemiological-update-on-covid-19---15-june-2022#:~:text=After%20five%20weeks%20of%20decline,deaths%20have%20been%20reported%20globally. Accessed Oct 22, 2024."},{"key":"1337_CR23","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2147\/CLEP.S239511","volume":"12","author":"KW Hagberg","year":"2020","unstructured":"Hagberg KW, Persson R, Vasilakis-Scaramozza C, et al. Herpes zoster, hepatitis\u00a0C, and tuberculosis risk with apremilast compared to biologics, DMARDs and corticosteroids to treat psoriasis and psoriatic arthritis. Clin Epidemiol. 2020;12:153\u201361.","journal-title":"Clin Epidemiol"},{"issue":"10 suppl","key":"1337_CR24","first-page":"S690","volume":"66","author":"D Fiorentino","year":"2014","unstructured":"Fiorentino D, Lebwohl M, Ho V, et al. Malignancies in the Psoriasis Longitudinal Assessment and Registry Study: cumulative experience [abstract 1563]. Arthritis Rheumatol. 2014;66(10 suppl):S690.","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"1337_CR25","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1111\/bjd.14068","volume":"173","author":"AB Kimball","year":"2015","unstructured":"Kimball AB, Schenfeld J, Accortt NA, Anthony MS, Rothman KJ, Pariser D. Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States. Br J Dermatol. 2015;173(5):1183\u201390.","journal-title":"Br J Dermatol"},{"issue":"24","key":"1337_CR26","doi-asserted-by":"publisher","first-page":"4251","DOI":"10.1002\/cncr.34479","volume":"128","author":"KA Cronin","year":"2022","unstructured":"Cronin KA, Scott S, Firth AU, et al. Annual report to the nation on the status of cancer, part 1: national cancer statistics. Cancer. 2022;128(24):4251\u201384.","journal-title":"Cancer"},{"key":"1337_CR27","unstructured":"SEER*Explorer: An interactive website for SEER cancer statistics. Surveillance Research Program, National Cancer Institute, 2023. https:\/\/seer.cancer.gov\/statistics-network\/explorer\/. Accessed Oct 22, 2024."},{"key":"1337_CR28","unstructured":"Cancer Facts & Figures 2020. American Cancer Society, 2020. https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2020\/cancer-facts-and-figures-2020.pdf. Accessed Oct 22, 2024."},{"issue":"1","key":"1337_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2016-000187","volume":"4","author":"S Bernatsky","year":"2017","unstructured":"Bernatsky S, Vel\u00e1squez Garc\u00eda HA, Spinelli JJ, et al. Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. Lupus Sci Med. 2017;4(1):e000187.","journal-title":"Lupus Sci Med"},{"issue":"3","key":"1337_CR30","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1001\/jamadermatol.2015.4847","volume":"152","author":"ZC Chiesa Fuxench","year":"2016","unstructured":"Chiesa Fuxench ZC, Shin DB, Ogdie Beatty A, Gelfand JM. The risk of cancer in patients with psoriasis: a population-based cohort study in the health improvement network. JAMA Dermatol. 2016;152(3):282\u201390.","journal-title":"JAMA Dermatol"},{"issue":"10","key":"1337_CR31","doi-asserted-by":"crossref","first-page":"13030","DOI":"10.5070\/D32410041706","volume":"24","author":"SR Feldman","year":"2018","unstructured":"Feldman SR, Hur P, Zhao Y, et al. Incidence rates of comorbidities among patients with psoriasis in the United States. Dermatol Online J. 2018;24(10):13030.","journal-title":"Dermatol Online J"},{"key":"1337_CR32","unstructured":"Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today. International Agency for Research on Cancer, 2021. https:\/\/gco.iarc.who.int\/today. Accessed June 10, 2024."},{"issue":"5","key":"1337_CR33","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1080\/10245332.2015.1115586","volume":"21","author":"F Ge","year":"2016","unstructured":"Ge F, Zhang Y, Cao F, et al. Arsenic trioxide-based therapy is suitable for patients with psoriasis-associated acute promyelocytic leukemia: a retrospective clinical study. Hematology. 2016;21(5):287\u201394.","journal-title":"Hematology"},{"issue":"3","key":"1337_CR34","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s40257-017-0337-2","volume":"19","author":"S Geller","year":"2018","unstructured":"Geller S, Xu H, Lebwohl M, Nardone B, Lacouture ME, Kheterpal M. Malignancy risk and recurrence with psoriasis and its treatments: a concise update. Am J Clin Dermatol. 2018;19(3):363\u201375.","journal-title":"Am J Clin Dermatol"},{"issue":"Suppl 3","key":"1337_CR35","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/jdv.12165","volume":"27","author":"C Pouplard","year":"2013","unstructured":"Pouplard C, Brenaut E, Horreau C, et al. Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies. J Eur Acad Dermatol Venereol. 2013;27(Suppl 3):36\u201346.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1337_CR36","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1001\/jamadermatol.2020.0024","volume":"156","author":"S Vaengebjerg","year":"2020","unstructured":"Vaengebjerg S, Skov L, Egeberg A, Loft ND. Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. JAMA Dermatol. 2020;156(4):421\u20139.","journal-title":"JAMA Dermatol"},{"issue":"7","key":"1337_CR37","first-page":"706","volume":"14","author":"K Papp","year":"2015","unstructured":"Papp K, Gottlieb AB, Naldi L, et al. Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR). J Drugs Dermatol. 2015;14(7):706\u201314.","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"1337_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018125","volume":"6","author":"O Ahlehoff","year":"2011","unstructured":"Ahlehoff O, Gislason GH, Lindhardsen J, et al. Psoriasis carries an increased risk of venous thromboembolism: a Danish nationwide cohort study. PLoS ONE. 2011;6(3):e18125.","journal-title":"PLoS ONE"},{"issue":"20 Suppl","key":"1337_CR39","first-page":"S376","volume":"23","author":"HM Phillippe","year":"2017","unstructured":"Phillippe HM. Overview of venous thromboembolism. Am J Manag Care. 2017;23(20 Suppl):S376\u201382.","journal-title":"Am J Manag Care"},{"key":"1337_CR40","unstructured":"FDA Briefing Document Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19. Vaccines and Related Biological Products Advisory Committee Meeting February 26, 2021. US Food and Drug Administration, 2022. https:\/\/www.fda.gov\/media\/146217\/download. Accessed Oct 22, 2024."},{"issue":"2","key":"1337_CR41","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/art.42391","volume":"75","author":"E Morand","year":"2023","unstructured":"Morand E, Pike M, Merrill JT, et al. Deucravacitinib, a tyrosine kinase\u00a02 inhibitor, in systemic lupus erythematosus: a phase\u00a0II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2023;75(2):242\u201352.","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 1","key":"1337_CR42","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1136\/annrheumdis-2022-eular.2456","volume":"81","author":"PJ Mease","year":"2022","unstructured":"Mease PJ, Deodhar A, Van der Heijde D, et al. Safety and efficacy of deucravacitinib, an oral, selective tyrosine kinase\u00a02 inhibitor, in patients with psoriatic arthritis: 52-week results from a randomised phase\u00a02 trial [abstract POS1048]. Ann Rheum Dis. 2022;81(Suppl 1):842\u20133.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1337_CR43","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316\u201326.","journal-title":"N Engl J Med"},{"issue":"8","key":"1337_CR44","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1111\/jdv.19925","volume":"38","author":"B Strober","year":"2024","unstructured":"Strober B, Blauvelt A, Warren RB, et al. Deucravacitinib in moderate to severe plaque psoriasis: pooled safety and tolerability over 52\u00a0weeks from two phase\u00a03 trials (POETYK PSO-1 and PSO-2). J Eur Acad Dermatol Venereol. 2024;38(8):1543\u201354.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01337-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01337-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01337-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:58:55Z","timestamp":1739840335000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01337-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1337"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01337-x","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"27 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mark Lebwohl is an Editorial Board member of\n                      Dermatology and Therapy\n                      . Mark Lebwohl was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Disclosure of potential conflict of interest: Joseph F. Merola has served as a consultant and\/or investigator for AbbVie, Amgen, Biogen, Bristol Myers Squibb, Dermavant, Janssen, Leo Pharma, Lilly, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, and UCB. Laura K. Ferris has served as an investigator for AbbVie, Acelyrin, Amgen, Apogee, Arcutis, Aristea, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, DermTech, Galderma, GRAIL, Incyte, Janssen, Leo Pharma, Lilly, Moberg, Mobius, Novartis, Regeneron, SkinAnalytics, Takeda, and UCB; consultant for AbbVie, Amgen, Apogee, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant, DermTech, Janssen, Leo Pharma, Novartis, Pfizer, Regeneron, and Takeda; speaker for AbbVie, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, and Regeneron. Jeffrey M. Sobell has served as a consultant, speaker, and\/or investigator for Amgen, AbbVie, Arcutis, Biogen, Bristol Myers Squibb, Dermavant, Janssen, Lilly, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB. Howard Sofen has served as a clinical investigator for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Leo Pharma, Lilly, Novartis, and Sun Pharma. John Osborne has served on a speakers bureau for Amarin, Boehringer Ingelheim, Esperion Therapeutics, Lilly, and Novo Nordisk. John Vaile, Ying-Ming Jou, Carolin Daamen, and Julie Scotto are employees of and shareholders in Bristol Myers Squibb. Thomas Scharnitz was an employee of and shareholder in Bristol Myers Squibb at the time of study conduct and is now an employee of Novartis. Mark Lebwohl is an employee of Mount Sinai and has received research funds from AbbVie, Arcutis, Avotres, Boehringer Ingelheim, Cara Therapeutics, Clexio, Dermavant, Incyte, Inozyme, Janssen, Lilly, Pfizer, Sanofi-Regeneron, and UCB,\u00a0and is a consultant for Almirall, AltruBio, Apogee, Arcutis, AstraZeneca, Atomwise, Avotres, Boehringer Ingelheim, Bristol Myers Squibb,\u00a0Castle Biosciences, Celltrion, CorEvitas Psoriasis Registry, Dermavant, Dermsquared, Evommune, Facilitation of International Dermatology Education, Forte Biosciences, Galderma, Genentech, Incyte, Leo Pharma, Meiji Seika Pharma, Mindera Health, Pfizer, Sanofi-Regeneron, Seanergy, Strata, Takeda, Trevi, and Verrica.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"These studies were conducted in accordance with the ethical principles of the Declaration of Helsinki and Good Clinical Practice guidelines of the International Council for Harmonisation and in accordance with the European Union Directive 2001\/20\/EC and the US Code of Federal Regulations, Title 21, Part 50 (21CFR50), as well as applicable local requirements. The study protocols and amendments were approved by an institutional review board or independent ethics committee before initiation of the study at each site. All patients or their legal representatives provided written informed consent prior to study participation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}